Inhibitors of enzymes involved in purine metabolism, such as IMPDH inhibitors and HPRT inhibitors, have shown promising results in preclinical studies and are being investigated for their potential therapeutic use in peritoneal cancers, including ovarian cancer [84]. This evidence concerns the gene HPRT1 and ovarian carcinoma.